Five Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBD
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) announced on Thursday the results from a preclinical study of its investigational cannabinoid Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog.